Mebella is another weapon in the global fight to eradicate these diseases.
Data from one study showed younger women more likely to use sunscreen than older adults.
The critical role of distributors amid natural disasters, and strategies to protect and maintain the pharma supply chain
What are some of the factors affecting whether a brand-name drug has generic competition?
Lefamulin was approved by the FDA in August 2019 for the treatment of CABP.
In many industries, tipping is the norm. Pharmacists would just like to receive payment for services rendered.
Solriamfetol (Sunosi, Jazz Pharmaceuticals) to treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea was approved on March 20, 2019.
Following the Federal Trade Commission’s interim report on PBMs, legislators are galvanized to make change happen.
It’s never too far into flu season to educate patients.
Most pharmacists are moderately to not-at-all comfortable answering patient questions about cannabis. That needs to change.
Pharmacies, just as expected, have showed up in meaningful ways to support their communities.
The FDA has approved lumateperone tosylate (Caplyta™, Intra-Cellular Therapies) for treatment of schizophrenia in adults.
Building literature evaluation skills is an essential teaching component during all stages of pharmacy education
In August 2019, the FDA approved entrectinib for treatment of adult patients with metastatic non-small cell lung cancer that is ROS1-positive.
In July 2019, the FDA approved darolutamide (Nubeqa, Bayer) for men with prostate cancer that has not spread (ie, nonmetastatic) and no longer responds to medical or surgical treatment that lowers testosterone (ie androgen deprivation therapy).
Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) is indicated for treating adults with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2–based regimens in the setting of metastasis.
Migraine is one of the most common neurologic disorders in children and adolescents with a prevalence of 7.7%.
Migraine is one of the most common neurologic disorders in children and adolescents with a prevalence of 7.7%.
A close look at their potential to interact with other medications is required to limit the risk of adverse outcomes for patients.
Medication decision support tools focused on individual patients can help pharmacists effectively analyze risk of unintended harm, identify and assess potential interventions, and facilitate longitudinal care.
Some patients affected by COVID-19 may be concerned about hyposmia (reduced ability to smell) or anosmia (loss of smell) that they experience after contracting the virus.
The gut-brain-skin axis is more important to overall health than previously understood, and prebiotics and probiotics play a large role in the benefits.
Nearly 25% of people “have vitamin D blood levels that are too low or inadequate for bone and overall health,” according to the NIH.
Zavegepant joins other CGRP antagonists as an option for individuals experiencing migraine.
Independent pharmacists, health care providers, community leaders, and law enforcement must all work together to address the fentanyl epidemic.
Careful thought and adjustments are required to avoid exceeding the maximum recommended amount.
Vaccines are important for everyone, but they’re critical for adults older than 65 years.
Developing innovative solutions for women with depression, accounting for differences in gender and sex, are critically important
Seasonal influenza kills hundreds of thousands of people every year due to a constantly changing virus and highly inefficient vaccine production. A universal flu vaccine could deal with the first problem, and mRNA technology with the second.